248 related articles for article (PubMed ID: 12829665)
21. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
22. Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy.
Bischof M; Zierhut D; Neuhof D; Karagiozidis M; Treiber M; Roeder F; Debus J; Krempien R
Ophthalmologica; 2007; 221(5):348-52. PubMed ID: 17728558
[TBL] [Abstract][Full Text] [Related]
23. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
24. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
Senff NJ; Hoefnagel JJ; Neelis KJ; Vermeer MH; Noordijk EM; Willemze R;
Arch Dermatol; 2007 Dec; 143(12):1520-6. PubMed ID: 18087001
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
[TBL] [Abstract][Full Text] [Related]
26. Radiation therapy for localized low-grade non-Hodgkin's lymphomas.
Tsang RW; Gospodarowicz MK
Hematol Oncol; 2005 Mar; 23(1):10-7. PubMed ID: 16158458
[TBL] [Abstract][Full Text] [Related]
27. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease.
Ahmed S; Kussick SJ; Siddiqui AK; Bhuiya TA; Khan A; Sarewitz S; Steinberg H; Sison CP; Rai KR
Eur J Cancer; 2004 Jun; 40(9):1320-6. PubMed ID: 15177490
[TBL] [Abstract][Full Text] [Related]
28. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
29. Radiation therapy for orbital lymphoma.
Zhou P; Ng AK; Silver B; Li S; Hua L; Mauch PM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):866-71. PubMed ID: 15925453
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients.
Uno T; Isobe K; Shikama N; Nishikawa A; Oguchi M; Ueno N; Itami J; Ohnishi H; Mikata A; Ito H
Cancer; 2003 Aug; 98(4):865-71. PubMed ID: 12910532
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study.
Yamashita H; Nakagawa K; Asari T; Murakami N; Igaki H; Ohtomo K
Radiother Oncol; 2008 Jun; 87(3):412-7. PubMed ID: 18423914
[TBL] [Abstract][Full Text] [Related]
32. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa.
Lee JL; Kim MK; Lee KH; Hyun MS; Chung HS; Kim DS; Shin SO; Cho HS; Bae SH; Ryoo HM
Ann Hematol; 2005 Jan; 84(1):13-8. PubMed ID: 15309523
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.
Guadagnolo BA; Li S; Neuberg D; Ng A; Hua L; Silver B; Stevenson MA; Mauch P
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):928-34. PubMed ID: 16243446
[TBL] [Abstract][Full Text] [Related]
34. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
36. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
[TBL] [Abstract][Full Text] [Related]
37. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
[TBL] [Abstract][Full Text] [Related]
38. Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification.
Sakata K; Satoh M; Someya M; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
Strahlenther Onkol; 2005 Jun; 181(6):385-91. PubMed ID: 15925981
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
